Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Dice Therapeutics (DICE)
NASDAQ:DICE
Holding DICE?
Track your performance easily
See the Price Targets and Ratings of:
DICE Analyst Ratings
Hold
0 Buy
8 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
DICE Stock 12 Month Forecast
Average Price Target
$48.00
▲(0.95% Upside)
| Highest Price Target$48.00 | Average Price Target$48.00 | Lowest Price Target$48.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$48
Hold
0.95%
Upside
Reiterated
08/09/23
Analysts Conflicted on These Healthcare Names: Dice Therapeutics (NASDAQ: DICE) and Haemonetics (NYSE: HAE)
Needham
―
Hold
―
Downgraded
06/26/23
Needham Company downgrades DICE Therapeutics (DICE) to HoldNeedham Company analyst Serge Belanger downgraded DICE Therapeutics (NASDAQ: DICE) from Buy to Hold.
SVB Securities
$48
Hold
0.95%
Upside
Downgraded
06/21/23
Dice Therapeutics (DICE) Receives a New Rating from a Top Analyst
TD Cowen
―
Hold
―
Downgraded
06/21/23
Dice Therapeutics (DICE) downgraded to Market Perform from Outperform at TD Cowen
Evercore ISI
―
Hold
―
Downgraded
06/20/23
Dice Therapeutics downgraded to In Line from Outperform at Evercore ISIDice Therapeutics downgraded to In Line from Outperform at Evercore ISI
Stifel Nicolaus
$48
Hold
0.95%
Upside
Downgraded
06/20/23
Dice Therapeutics (DICE) downgraded to Hold from Buy at Stifel
Cantor Fitzgerald
$48
Hold
0.95%
Upside
Downgraded
06/20/23
Dice Therapeutics downgraded to Neutral from Overweight at Cantor FitzgeraldDice Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
Canaccord Genuity
$48
Hold
0.95%
Upside
Downgraded
06/20/23
Dice Therapeutics (DICE) Receives a Hold from Wells Fargo - TipRanks.comDice Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $56.17, representing a 20.95% upside. In a report released today, Canaccord Genuity also downgraded the stock to a Hold with a $48.00 price target.
Guggenheim
―
Buy
―
Reiterated
03/20/23
We highlight (1) IL-19 biomarker data from DC-806's Ph1 supports the potential for biologic-like efficacy of DC-806/853; (2) TAK's TAK-279 (TYK2) data heats up competition in the TYK2 space, but we still see advantages with the IL-17 mechanism in PsO, PsA, AxSpa, and HS; and (3) IL-17 is a validated target in HS with new datasets from UCB SA's bemikizumab and Acelyrin's izokibep (and previous data from NOVN-SWX's Cosentyx); we believe there is a large opportunity for an oral IL-17 small molecule in HS.
Bank of America Securities
$59
Buy
24.08%
Upside
Reiterated
03/20/23
We attended the American Academy Dermatology (AAD) conference in New Orleans given derm is a key therapeutic category for emerging orally dosed drugs aimed at targets historically addressed with injectable biologics. In 2H22, DICE emerged as a credible clinical-stage player in I&I with its oral IL-17 (similar to Cosentyx) with initial data in psoriasis (PsO). Over the weekend, we provided our thoughts (see report) on late-breaking DICE and competitor presentations relevant to PsO which could shape the future PsO treatment landscape.
Best Analysts Covering Dice Therapeutics
Which Analyst Should I Follow If I Want to Buy DICE and Sell After:
1 Month
xxx
Success Rate
1/3 ratings generated profit
Average Return
-1.53%
reiterated a xxx
rating 2 years ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 33.33% of your transactions generating a profit, with an average return of -1.53% per trade.
3 Months
xxx
Success Rate
1/3 ratings generated profit
Average Return
-12.50%
reiterated a xxx
rating 2 years ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 33.33% of your transactions generating a profit, with an average return of -12.50% per trade.
1 Year
Success Rate
3/3 ratings generated profit
Average Return
+45.80%
reiterated a buy rating 2 years ago
Copying Jason Gerberry's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +45.80% per trade.
2 Years
xxx
Success Rate
3/3 ratings generated profit
Average Return
+56.33%
reiterated a xxx
rating 2 years ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +56.33% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
DICE Analyst Recommendation Trends
Currently, no data available
Please return soon. This page is being updated.
Each month's total comprises the sum of three months' worth of ratings.
DICE Financial Forecast
DICE Stock Forecast FAQ
What is DICE’s average 12-month price target, according to analysts?
Based on analyst ratings, Dice Therapeutics’s 12-month average price target is $48.00.
What is DICE’s upside potential, based on the analysts’ average price target?
Dice Therapeutics has 0.95% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is DICE a Buy, Sell or Hold?
Dice Therapeutics has a consensus rating of Hold which is based on 0 buy ratings, 8 hold ratings and 0 sell ratings.
What is Dice Therapeutics’s price target?
The average price target for Dice Therapeutics is $48.00. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $48.00 ,the lowest forecast is $48.00. The average price target represents 0.95% Increase from the current price of $47.55.
The highest analyst price target is $48.00 ,the lowest forecast is $48.00. The average price target represents 0.95% Increase from the current price of $47.55.
What do analysts say about Dice Therapeutics?
Dice Therapeutics’s analyst rating consensus is a Hold. This is based on the ratings of 8 Wall Streets Analysts.
How can I buy shares of DICE?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.